Key statistics dashboard for Ligand Pharmaceuticals Incorporated (LGND). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Ligand Pharmaceuticals Incorporated operates as a biopharmaceutical entity, primarily engaged in sourcing and advancing technologies to empower pharmaceutical companies globally in their efforts to discover and develop novel therapeutic solutions. Its diverse portfolio of commercialized products addresses a wide range of medical conditions.
Stock Data
| Price | $284.47 |
| Market Cap | $5.7B |
| Enterprise Value | $5.64B |
| Beta | 1.00 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | 27.49 |
| Price / Book | 5.71 |
| P/S | 18.98 |
| EV/EBITDA | 20.60 |
| EV/Sales | 19.41 |
| EV/FCF | 42.93 |
| P/FCF | 41.98 |
| Earnings Yield | 3.57% |
| FCF Yield | 2.38% |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 98.58% |
| EBIT Margin | 82.50% |
| EBITDA Margin | 94.22% |
| Operating Margin | 34.74% |
| Net Margin | 67.88% |
| Return on Equity | 20.06% |
| Return on Assets | 9.02% |
| Return on Invested Capital | 3.91% |
| Return on Capital Employed | 4.72% |
Financial Health
| Current Ratio | 31.18 |
| Quick Ratio | 30.96 |
| Cash Ratio | 21.54 |
| Debt / Equity | 1.17 |
| Debt / Assets | 51.76% |
| Net Debt / EBITDA | 0.46 |
| Interest Coverage | 16.31 |
Per-Share Data
| Revenue per share | 14.48 |
| Book Value per share | 48.22 |
| Cash per share | 67.67 |
| FCF per share | 6.55 |
| Tangible Book Value per share | 32.73 |
| Dividend per share | 0.00 |
Related companies: ACAD · ADMA · BLTE · CRNX · DYN · MIRM · NAMS
Explore sector: Healthcare · Biotechnology
More sections of LGND: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks